GSK has stopped development of anti-TIGIT antibody belrestotug. | GSK has stopped development of anti-TIGIT antibody ...

The failure is the latest stumble for a cancer drug class that hasn’t lived up to expectations. iTeos will begin a strategic ...

GSK said it is axing development of belrestotug and concluding its iTeos collaboration, which began with $625 million upfront ...

Britain's GSK and drug developer iTeos Therapeutics said on Tuesday they have stopped developing an experimental lung cancer ...

Teos Therapeutics faces significant setbacks with the discontinuation of their TIGIT program and belrestotug, leaving them ...

Belgian clinical-stage biotech iTeos Therapeutics (Nasdaq: ITOS) saw its shar leap18.6% to $8.20 today, despite posting ...

GSK's CD96 candidate GSK'608 is in phase 1 testing, while PVRIG drug GSK'562 is in preclinical development. Under the terms of the deal, GSK gets rights to co-commercialise the TIGIT antibody in ...

The failure of Roche's tiragolumab in the SKYSCRAPER-01 trial in on-small cell lung cancer (NSCLC) has cast a pall over the TIGIT class, but iTeos said it is committed with GSK to completing their ...

GSK Plc and iTeos Therapeutics ended the development of an experimental lung cancer drug, the latest in a series of setbacks ...

The drug was being developed as a potential treatment for various cancers. GSK said it is expanding from its current focus on blood and women's cancers into lung and gastrointestinal cancers, as well ...

Despite the unfavorable trial results, iTeos Therapeutics has initiated a strategic review to maximize shareholder value. The company’s CEO, Michel Detheux, Ph.D., expressed disappointment over the ...